Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.47 |
| ▸ | NPC1 | O15118 | 7/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 3/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3826237 | 0.87 | CYP3A4 (0.53) | RAB9ANPC1TRPV1SMN1; SMN2HPGD | |
| SCHEMBL989336 | 0.85 | TRPV1 (0.44) | RAB9ANPC1TRPV1NAMPTSMN1; SMN2 | |
| SCHEMBL986981 | 0.84 | TRPV1 (0.44) | TRPV1NAMPTHPGDHTTHSD17B10 | |
| SCHEMBL3828968 | 0.83 | TRPV1 (0.45) | TRPV1HTTHSD17B10CYP3A4 | |
| SCHEMBL987860 | 0.83 | TRPV1 (0.45) | RAB9ANPC1TRPV1MEN1KMT2A | |
| SCHEMBL1781223 | 0.83 | RAB9A (0.47) | RAB9ANPC1TRPV1MEN1KMT2A | |
| SCHEMBL10820464 | 0.83 | TYK2 (0.48) | TRPV1HTTHSD17B10MAPTLMNA | |
| SCHEMBL10819913 | 0.83 | TRPV1 (0.43) | RAB9ANPC1TRPV1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL3559784 | 0.83 | TRPV1 (0.44) | RAB9ANPC1TRPV1MEN1KMT2A | |
| SCHEMBL1783734 | 0.83 | TRPV1 (0.44) | RAB9ANPC1TRPV1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130303542-A1 | SUBSTITUTED PYRAZINAMIDE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2013-11-14 | — | — | US | disclosed |
| US-20130303542-A1 | SUBSTITUTED PYRAZINAMIDE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2013-11-14 | — | — | US | disclosed |
| US-20120183579-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120183579-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20110118281-A9 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. | 2011-05-19 | — | — | US | disclosed |
| US-20110118281-A9 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. | 2011-05-19 | — | — | US | disclosed |
| US-20110118281-A9 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. | 2011-05-19 | — | — | US | disclosed |
| US-20100125080-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. | 2010-05-20 | — | — | US | disclosed |
| US-20100125080-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. | 2010-05-20 | — | — | US | disclosed |
| US-20100125080-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. | 2010-05-20 | — | — | US | disclosed |
| WO-2010039236-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303542-A1 | SUBSTITUTED PYRAZINAMIDE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | NLRP3, NLRP1, CXCL8 | RAB9A 1786/4885NPC1 661/4885PPARG 34/4885 |
| US-20100125080-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCL8, CCR1, CCR8 | RAB9A 1852/4885NPC1 199/4885PPARG 142/4885 |
| US-20120183579-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCL8, CCR1, CCR8 | RAB9A 1852/4885NPC1 199/4885PPARG 142/4885 |
| US-20110118281-A9 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCL8, CCR1, CCR8 | RAB9A 1852/4885NPC1 199/4885PPARG 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.